Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis

International policy for treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR TB) relies largely on individual patient data (IPD) from observational studies of patients treated under routine conditions. We prepared guidance on which data to collect and what measures could improve cons...

Full description

Saved in:
Bibliographic Details
Published in:Emerging infectious diseases 2020-03, Vol.26 (3)
Main Authors: Campbell, Jonathon R, Falzon, Dennis, Mirzayev, Fuad, Jaramillo, Ernesto, Migliori, Giovanni Battista, Mitnick, Carole D, Ndjeka, Norbert, Menzies, Dick
Format: Article
Language:English
Subjects:
Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
Clinical outcomes
Clinical practice guidelines
Data collection
data collection standards
Data dictionaries
evidence-based medicine
Humans
Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis
Laboratories
Meta-analysis
multidrug resistance
Mycobacterium tuberculosis - drug effects
Observational Studies as Topic - standards
Online Report
Patients
Quality Improvement
Rifampin - pharmacology
Rifampin - therapeutic use
therapy data collection
Tuberculosis
Tuberculosis, Multidrug-Resistant - drug therapy
Tuberculosis, Pulmonary - drug therapy
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:International policy for treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR TB) relies largely on individual patient data (IPD) from observational studies of patients treated under routine conditions. We prepared guidance on which data to collect and what measures could improve consistency and utility for future evidence-based recommendations. We highlight critical stages in data collection at which improvements to uniformity, accuracy, and completeness could add value to IPD quality. Through a repetitive development process, we suggest essential patient- and treatment-related characteristics that should be collected by prospective contributors of observational IPD in MDR/RR TB.
ISSN:1080-6040
1080-6059
DOI:10.3201/eid2603.190997